 TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 114309-1007
Re Application Of: Gerald H rn			
Serial No. 09/854,414	Filing Date May 10, 2001	Examiner Z. Fay	Group Art Unit 1614
Title: OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE			
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			
37 CFR 1.97(b)			
1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.			
37 CFR 1.97(c)			
2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:			
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>			
OR			
<div style="margin-left: 40px;"> <input checked="" type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>			

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
114309-1007

Re Application: **Gerald Horn**

Serial No.
09/854,414

Filing Date
May 10, 2001

Examiner
Z. Fay

Group Art Unit
1614

OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **02-1818**
as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on **12-19-2003** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Renee Street

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: **December 19, 2003**

Robert M. Barrett
Reg. No. 30,142
BELL, BOYD & LLOYD LLC
P.O. B x 1135
Chicago, IL 60690-1135
Phone: 312-807-4204

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerald Horn
Appl. No.: 09/854,414
Conf. No.: 7675
Filed: May 10, 2001
Title: OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE
Art Unit: 1614
Examiner: Z. Fay
Docket No.: 114309-1007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
4,515,295	May 7, 1985	Dougherty
4,629,456	December 16, 1986	Edwards
4,834,727	May 30, 1989	Cope
4,906,613	March 6, 1990	Watkins
5,059,188	October 22, 1991	Goddard
5,134,124	July 28, 1992	Nisato et al.
5,514,118	May 7, 1996	Kummer et al.
5,584,823	December 17, 1996	Valberg
5,591,426	January 7, 1997	Dabrowski et al.
5,627,611	May 6, 1997	Scheiner
5,792,767	August 11, 1998	Meyer et al.
5,891,882	April 6, 1999	Meyer et al.
5,891,913	April 6, 1999	Sallmann et al.
5,895,654	April 20, 1999	Hartford

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZF/

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
6,046,207	April 4, 2000	Meyer et al.
09/675,988	September 29, 2000	Horn
09/705,526	November 3, 2000	Horn
6,291,498	September 18, 2001	Horn
6,420,407	July 16, 2002	Horn
2002/008228	June 27, 2002	Horn
6,515,006	February 4, 2003	Horn

OTHER DOCUMENTS

Bedford Laboratories, *Phentolamine Mesylate for Injection, USP*, May 1999.

Van Alphen, G., *The adrenergic receptors of the intraocular muscles of the human eye*, Investigative Ophthalmology, June 1976, Vol. 15, No. 6, pp. 502-505.

Yoshitomi, T., et al., *Adrenergic Excitatory and Cholinergic Inhibitory Innervations in the Human Iris Dilator*, Exp. Eye Res. 1998, Vol. 40, pp. 453-459.

Lee, Y.C., et al., *Influence of dioptric correction and pupil size on visual function*, J. Cataract Refract. Surg., 2003, Vol. 29, pp. 769-777.

Thordsen, J.E., et al., *Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eye*, April 25, 2003.

Padma-Nathan, H., et al., *Long-term safety and efficacy of oral phentolamine mesylate (Vasomar) in men with mild to moderate erectile dysfunction*, International Journal of Impotence Research, August 2002, Vol. 14, No. 4., pp. 266-270.

Heller, P.H., et al., *Autonomic components of the human pupillary light reflex*, Investigate Ophthalmology & Visual Science, Vo. 31, No. 1, January 1990, pp. 156-162.

King, V.M., *Effects of mydriatics and a miotic on ocular discomfort and pupil responses*, Journal of the American Optometric Association, Vol. 47, No. 7, July 1976, pp. 937-942.

Hill, C.E., et al., *Specificity of Innervation of Iris Musculature by Sympathetic Nerve Fibres in Tissue Culture*, Pflügers Arch., 1976, Vol. 361, pp. 127-134.

Lograno, M.D., et al., *Receptor-responses in fresh human ciliary muscle*, Br. J. Pharmac., 1986, Vol. 87, pp. 379-385.

Zetterström, C., et al., *Pharmacological Characterization of Human Ciliary Muscle Adrenoceptors in Vitro*, Exp. Eye Res., 1988, Vol. 46, pp. 421-430.

- Takayanagi, I., et al., *α_{1B} -Adrenoceptor Mechanisms in Rabbit Iris Dilator*, Japan. J. Pharmacol., 1992, Vol. 59, pp. 301-305.
- Ishikawa, H., et al., *Comparison of post-junctional α -adrenoceptors in iris dilator muscle of humans, and albino and pigmented rabbits*, Naun. Schmed., 1996, Vol. 354, pp. 165-172.
- Yu, Y., et al., *α_{1A} -Adrenoceptors Mediate Sympathetically Evoked Pupillary Dilation in Rats*, JPET, February 2002, Vol. 300, Issue 2, pp. 521-525.
- Benson, G.S., et al., *Is Phentolamine Stable in Solution with Papaverine*, The Journal of Urology, November 1988, Vol. 140, pp. 970-971.
- Hadzija, B.W., et al., *Physicochemical Stability of Papaverine Hydrochloride-phentolamine Mesylate Mixtures used for Intracavernous Injection: A Preliminary Evaluation*, The Journal of Urology, January 1988, Vol. 140, pp. 64-65.
- Soli, M., et al., *Vasoactive Cocktails for Erectile Dysfunction: Chemical Stability of PGE1, Papaverine and Phentolamine*, The Journal of Urology, August 1998, Vol. 160, pp. 551-555.
- Tu, Y.H., et al., *Stability of papaverine hydrochloride and phentolamine mesylate in injectable mixtures*, American Journal of Hospital Pharmacy, Vol. 44, November 1987, pp. 2524-2527.
- Wang, D.P., et al., *Degradation Kinetics of Phentolamine Hydrochloride in Solution*, Journal of Pharmaceutical Sciences, November 1988, Vol. 77, No. 11, pp. 972-976.
- H. Uusitalo, *An acute ocular inflammatory reaction induced by intravitreal bovine serum albumin in presensitized rabbits: the effect of phentolamine*, Acta. Ophthalmol. (Copenh), August 1994, Vol. 63, No. 4, pp. 636-642.
- H. Uusitalo, *The effect of autonomic receptor blockers on the ocular response to topical chemical irritation*, Acta. Physiol. Scand., May 1984, Vol. 121, No. 1, pp. 1-8.
- Davies, NM: *Biopharmaceutical considerations in topical ocular drug delivery*, Clin. Exp. Pharmacol. Physiol., 2000, Vol. 27, No. 7, pp. 558-562.
- Alster, Y., et al., *Dapiprazole for patients with night haloes after excimer keratectomy*, Graefe's Arch. Clin. Exp. Ophthalmol., 1996, Vol. 234, pp. S139-S141.
- McDonald II, J.E., et al., *Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions*, J. Cataract Refract. Surg., April 2001, Vol. 27, pp. 560-564.
- O'Brart, D.P.S., et al., *Disturbances in night vision after excimer laser photorefractive keratectomy*, Eye, 1994, Vol. 8, pp. 46-51.

Fan-Paul, N.I., et al., *Night Vision Disturbances After Corneal Refractive Surgery*, Survey of Ophthalmology, November-December 2002, Vol. 47, No. 6, pp. 533-546.

Connor, C.G., et al., *The clinical efficacy of Rēv-Eyes™ in reversing the effects of pupillary dilation*, Journal of the American Optometric Association, J. Am. Optom. Assoc., 1993, Vol. 64, pp. 634-636.

O'Brart, D.P.S., et al., *Night vision after excimer laser photorefractive keratectomy: haze and halos*, European Journal of Ophthalmology, 1994, Vol. 4, No. 1, pp. 43-51.

Nielsen, C.B., et al., *Effect of α - and β -receptor active drugs on corneal thickness*, Acta Ophtahal., 1985, Vol. 63, pp. 351-354.

Goodman & Gillman's *The Pharmacological Basis of Therapeutics*, (Ninth Edition) at pp. 225-232.

Nicola Iuglio, MD, *Ocular Effects of Topical Application of Dapiprazole in Man*, Glaucoma, 1984, Vol. 6, pp. 110-116.

Chou B., et al., *The Role of Pupil Size in Refractive Surgery*, February, 2001, www.refractivessource.com/doctors/clinical_pearls/role_pupil.htm.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC


BY _____

Robert M. Barrett
Reg. No. 30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204

Dated: December 19, 2003



**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

PTO Form 1449

Atty Docket No. 114309-1007	Application No. 09/854,414
Applicant Gerald Horn	
Filing Date May 10, 2001	Group 1614


U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	4,515,295	05-07-85	Dougherty			
	4,629,456	12-16-86	Edwards			
	4,834,727	05-30-89	Cope			
	4,906,613	03-06-90	Watkins			
	5,059,188	10-22-91	Goddard			
	5,134,124	07-28-92	Nisato et al.			
	5,514,118	05-07-96	Kummer et al.			
	5,584,823	12-17-96	Valberg			
	5,591,426	01-07-97	Dabrowski et al.			
	5,627,611	05-06-97	Scheiner			
	5,792,767	08-11-98	Meyer et al.			
	5,891,882	04-06-99	Meyer et al.			
	5,891,913	04-06-99	Sallmann et al.			
	5,895,654	04-2099	Hartford			
	6,046,207	04-04-00	Meyer et al.			
	✓ 09/675,988	09-29-00	Horn			
	✓ 09/705,526	11-03-00	Horn			
	6,291,498	09-18-01	Horn			
	6,420,407	07-16-02	Horn			
	✓ 2002/0082288	06-27-02	Horn			
	6,515,006	02-04-03	Horn			

FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
------------------------	---

Examiner: /Zohreh Fay/ (05/11/2011)	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZF/



**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)


PTO Form 1449

Atty Docket No. 114309-1007	Application No. 09/854,414
Applicant Gerald Horn	
Filing Date May 10, 2001	Group 1614

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Bedford Laboratories, Phentolamine Mesylate for Injection, USP, May 1999.
	Van Alphen, G., <i>The adrenergic receptors of the intraocular muscles of the human eye</i> , Investigative Ophthalmology, June 1976, Vol. 15, No. 6, pp. 502-505.
	Yoshitomi, T., et al., <i>Adrenergic Excitatory and Cholinergic Inhibitory Innervations in the Human Iris Dilator</i> , Exp. Eye Res. 1998, Vol. 40, pp. 453-459.
	Lee, Y.C., et al., <i>Influence of dioptric correction and pupil size on visual function</i> , J. Cataract Refract. Surg., 2003, Vol. 29, pp. 769-777.
	Thordsen, J.E., et al., <i>Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eye</i> , April 25, 2003.
	Padma-Nathan, H., et al., <i>Long-term safety and efficacy of oral phentolamine mesylate (Vasomar) in men with mild to moderate erectile dysfunction</i> , International Journal of Impotence Research, August 2002, Vol. 14, No. 4., pp. 266-270.
	Heller, P.H., et al., <i>Autonomic components of the human pupillary light reflex</i> , Investigate Ophthalmology & Visual Science, Vo. 31, No. 1, January 1990, pp. 156-162.
	King, V.M., <i>Effects of mydriatics and a miotic on ocular discomfort and pupil responses</i> , Journal of the American Optometric Association, Vol. 47, No. 7, July 1976, pp. 937-942.
	Hill, C.E., et al., <i>Specificity of Innervation of Iris Musculature by Sympathetic Nerve Fibres in Tissue Culture</i> , Pflügers Arch., 1976, Vol. 361, pp. 127-134.
✓	Lograno, M.D., et al., <i>Receptor-responses in fresh human ciliary muscle</i> , Br. J. Pharmac., 1986, Vol. 87, pp. 379-385.
✓	Zetterström, C., et al., <i>Pharmacological Characterization of Human Ciliary Muscle Adrenoceptors in Vitro</i> , Exp. Eye Res., 1988, Vol. 46, pp. 421-430.
✓	Takayanagi, I., et al., <i>α_{1B}-Adrenoceptor Mechanisms in Rabbit Iris Dilator</i> , Japan. J. Pharmacol., 1992, Vol. 59, pp. 301-305.
✓	Ishikawa, H., et al., <i>Comparison of post-junctional α-adrenoceptors in iris dilator muscle of humans, and albino and pigmented rabbits</i> , Naun. Schmed., 1996, Vol. 354, pp. 165-172.
✓	Yu, Y., et al., <i>α_{1A}-Adrenoceptors Mediate Sympathetically Evoked Pupillary Dilation in Rats</i> , JPET, February 2002, Vol. 300, Issue 2, pp. 521-525.
✓	Benson, G.S., et al., <i>Is Phentolamine Stable in Solution with Papaverine</i> , The Journal of Urology, November 1988, Vo. 140, pp. 970-971.
✓	Hadzija, B.W., et al., <i>Physicochemical Stability of Papaverine Hydrochloride-phentolamine Mesylate Mixtures used for Intracavernous Injection: A Preliminary Evaluation</i> , The Journal of Urology, January 1988, Vol. 140, pp. 64-65.
✓	Soli, M., et al., <i>Vasoactive Cocktails for Erectile Dysfunction: Chemical Stability of PGE1, Papaverine and Phentolamine</i> , The Journal of Urology, August 1998, Vol. 160, pp. 551-555.

Examiner: /Zohreh Fay/ (05/11/2011)	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZF/



INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) PTO Form 1449	Atty Docket No. 114309-1007	Application No. 09/854,414
	Applicant Gerald Horn	
	Filing Date May 10, 2001	Group 1614

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
✓	Tu, Y.H., et al., <i>Stability of papaverine hydrochloride and phentolamine mesylate in injectable mixtures</i> , American Journal of Hospital Pharmacy, Vol. 44, November 1987, pp. 2524-2527.
✓	Wang, D.P., et al., <i>Degradation Kinetics of Phentolamine Hydrochloride in Solution</i> , Journal of Pharmaceutical Sciences, November 1988, Vol. 77, No. 11, pp. 972-976.
✓	H. Uusitalo, <i>An acute ocular inflammatory reaction induced by intravitreal bovine serum albumin in presensitized rabbits: the effect of phentolamine</i> , Acta. Ophthalmol. (Copenh), August 1994, Vol. 63, No. 4, pp. 636-642.
✓	H. Uusitalo, <i>The effect of autonomic receptor blockers on the ocular response to topical chemical irritation</i> , Acta. Physiol. Scand., May 1984, Vol. 121, No. 1, pp. 1-8.
✓	Davies, NM: <i>Biopharmaceutical considerations in topical ocular drug delivery</i> , Clin. Exp. Pharmacol. Physiol., 2000, Vol. 27, No. 7, pp. 558-562.
✓	Alster, Y., et al., <i>Dapiprazole for patients with night haloes after excimer keratectomy</i> , Graefe's Arch. Clin. Exp. Ophthalmol., 1996, Vol. 234, pp. S139-S141.
✓	McDonald II, J.E., et al., <i>Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions</i> , J. Cataract Refract. Surg., April 2001, Vol. 27, pp. 560-564.
✓	O'Brart, D.P.S., et al., <i>Disturbances in night vision after excimer laser photorefractive keratectomy</i> , Eye, 1994, Vol. 8, pp. 46-51.
✓	Fan-Paul, N.I., et al., <i>Night Vision Disturbances After Corneal Refractive Surgery</i> , Survey of Ophthalmology, November-December 2002, Vol. 47, No. 6, pp. 533-546.
✓	Connor, C.G., et al., <i>The clinical efficacy of Rēv-Eyes™ in reversing the effects of pupillary dilation</i> , Journal of the American Optometric Association, J. Am. Optom. Assoc., 1993, Vol. 64, pp. 634-636.
✓	O'Brart, D.P.S., et al., <i>Night vision after excimer laser photorefractive keratectomy: haze and halos</i> , European Journal of Ophthalmology, 1994, Vol. 4, No. 1, pp. 43-51.
✓	Nielsen, C.B., et al., <i>Effect of α- and β-receptor active drugs on corneal thickness</i> , Acta Ophtahal., 1985, Vol. 63, pp. 351-354.
✓	Goodman & Gillman's <i>The Pharmacological Basis of Therapeutics</i> , (Ninth Edition) at pp. 225-232.
✓	Nicola Iuglio, MD, <i>Ocular Effects of Topical Application of Dapiprazole in Man</i> , Glaucoma, 1984, Vol. 6, pp. 110-116.
✓	Chou B., et al., <i>The Role of Pupil Size in Refractive Surgery</i> , February, 2001, www.refractivessource.com/doctors/clinical_pearls/role_pupil.htm .

Examiner: /Zohreh Fay/ (05/11/2011)	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZF/